ADVERTISEMENT
GW Pharma`s Cannabis Drug Fails in Cancer Pain Study
By Reuters Staff
LONDON (Reuters) - An experimental cannabis drug failed to alleviate pain in advanced cancer patients as hoped in a clinical study.
GW, which is developing the drug Sativex for pain in collaboration with Japan's Otsuka, said the first of three late-stage trials found no statistically significant difference between subjects using Sativex and those given a placebo.
"Although we missed the primary endpoint in this trial, based upon the positive data seen in the Phase 2 program, we remain confident in the ability for Sativex to relieve cancer pain in this patient population", said Justin Gover, GW's Chief Executive Officer.
"We have two additional pivotal Phase 3 trials ongoing which, if positive, would still allow us to submit a New Drug Application with the US FDA. We look forward to results from these two further studies later this year," he added.
(c) Copyright Thomson Reuters 2015. Click For Restrictions - https://about.reuters.com/fulllegal.asp
